Superficial adenocarcinoma of the esophagus

被引:109
作者
Rice, TW
Blackstone, EH
Goldblum, JR
DeCamp, MM
Murthy, SC
Falk, GW
Ormsby, AH
Rybicki, LA
Richter, JE
Adelstein, DJ
机构
[1] Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Ctr Swallowing & Esophageal Disorders, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Biostat & Epidemiol, Ctr Swallowing & Esophageal Disorders, Cleveland, OH 44195 USA
[3] Cleveland Clin Fdn, Dept Pathol Anat, Ctr Swallowing & Esphageal Disorders, Cleveland, OH 44195 USA
[4] Cleveland Clin Fdn, Dept Gastroenterol, Ctr Swallowing & Esophageal Disorders, Cleveland, OH 44195 USA
[5] Cleveland Clin Fdn, Dept Hematol & Oncol, Ctr Swallowing & Esophage Disorders, Cleveland, OH 44195 USA
关键词
D O I
10.1067/mtc.2001.113749
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Experience with treatment and outcome of superficial adenocarcinoma of the esophagus is limited. The purpose of this study was to evaluate the results of surgical management and identify predictors of survival. Methods: Between September 1985 and December 1999, 122 patients underwent resection. Eighty-nine percent were men (mean age 63 +/- 10 years; range 35-83 years). Sixty (49%) patients were in endoscopic surveillance programs and 48 (39%) had the preoperative diagnosis of high-grade dysplasia. Forced expiratory volume in 1 second was less than 2 L in 12 (12%). Seventy-five (61%) patients underwent transhiatal esophagectomy. Pathologic stage was N1 in 8 (7%). Pulmonary complications necessitating reintubation (respiratory failure) occurred in 10 (8%) patients. Time-related survival models were developed for decisionmaking (preoperative), prognosis (operative), and hospital care (postoperative). Results: Operative mortality was 2.5%. Survival at 1, 5, and 10 years was 89%, 77%, and 68%. Preoperative decision-making factors associated with ideal outcome were 1-second forced expiratory volume of more than 2 L, surveillance, preoperative diagnosis of high-grade dysplasia, and planned transhiatal esophagectomy. Prognosis was decreased in younger patients and in those with N1 disease. Postoperative respiratory failure increased mortality. Conclusions: Surgery is the treatment of choice for superficial adenocarcinoma of the esophagus. The ideal patient has a preoperative diagnosis of high-grade dysplasia found at surveillance, good pulmonary function, and undergoes a transhiatal esophagectomy. Discovery of N1 disease or development of postoperative respiratory failure reduces the benefits of surgery.
引用
收藏
页码:1077 / 1088
页数:12
相关论文
共 27 条
[1]   BARRETT-ESOPHAGUS - EFFECT OF ANTIREFLUX SURGERY ON SYMPTOM CONTROL AND DEVELOPMENT OF COMPLICATIONS [J].
ATTWOOD, SEA ;
BARLOW, AP ;
NORRIS, TL ;
WATSON, A .
BRITISH JOURNAL OF SURGERY, 1992, 79 (10) :1050-1053
[2]  
BASKERVILLE JC, 1982, TECHNOMETRICS, V24, P9
[3]  
Blackstone E H, 1992, J Heart Valve Dis, V1, P3
[4]   THE DECOMPOSITION OF TIME-VARYING HAZARD INTO PHASES, EACH INCORPORATING A SEPARATE STREAM OF CONCOMITANT INFORMATION [J].
BLACKSTONE, EH ;
NAFTEL, DC ;
TURNER, ME .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1986, 81 (395) :615-624
[5]  
Blot WJ, 1999, SEMIN ONCOL, V26, P2
[6]   Bagging predictors [J].
Breiman, L .
MACHINE LEARNING, 1996, 24 (02) :123-140
[7]   THE BOOTSTRAP AND IDENTIFICATION OF PROGNOSTIC FACTORS VIA COX PROPORTIONAL HAZARDS REGRESSION-MODEL [J].
CHEN, CH ;
GEORGE, SL .
STATISTICS IN MEDICINE, 1985, 4 (01) :39-46
[8]   Results of the Collis-Nissen gastroplasty in patients with Barrett's esophagus [J].
Chen, LQ ;
Nastos, D ;
Hu, CY ;
Chughtai, TS ;
Taillefer, R ;
Ferraro, P ;
Duranceau, AC .
ANNALS OF THORACIC SURGERY, 1999, 68 (03) :1014-1020
[9]   Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus:: Clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation [J].
Csendes, A ;
Braghetto, I ;
Burdiles, P ;
Puente, G ;
Korn, O ;
Díaz, JC ;
Maluenda, F .
SURGERY, 1998, 123 (06) :645-657
[10]  
Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.3.CO